Survodutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2805997-46-8

Survodutide (BI 456906) is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Boehringer Ingelheim, it is currently in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The peptide is designed to activate both incretin and glucagon signaling pathways, which together enhance energy expenditure and promote weight loss.

As a research-grade chemical, Survodutide is supplied in lyophilized powder form for laboratory use only. It is not intended for human or veterinary use, but serves as a valuable tool for studying the therapeutic potential of dual GLP-1/glucagon agonism in metabolic diseases.

Aplicaciones

• Obesity research: Investigating mechanisms of weight loss and energy metabolism.
• Metabolic disease studies: Exploring effects on insulin sensitivity and lipid profiles.
• MASH research: Evaluating potential for treating non-alcoholic steatohepatitis.
• Peptide pharmacology: Understanding dual receptor agonism and downstream signaling.

Pedidos y suministro

• Embalaje: Available in vials or bulk containers, custom packaging on request.
• Cantidad mínima de pedido: 5g
• Plazo de entrega: Typically 1-2 weeks after order confirmation.
• Documentación: COA, MSDS, and TDS provided with each shipment.

Solicitud de presupuesto

• Nuestra dirección: Calle Main, 280, Xi'an, Shaanxi, China
• LyvBio S.L. — Correo electrónico: info@lyvbio.com